Dr. Dreicer on an Alternate Sunitinib Schedule in mRCC

Robert Dreicer, MD
Published: Monday, Apr 01, 2013



Robert Dreicer, MD, MS, chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute and professor of Medicine at the Cleveland Clinic in Ohio, discusses a 2-weeks-on and 1-week-off (2/1) schedule of sunitinib for patients with metastatic renal cell carcinoma (mRCC).

The standard schedule for sunitinib is 4 weeks of treatment followed by 2 weeks of rest (4/2). On this schedule, patients are likely to experience toxicity and dose reductions that result in limited responses to treatment. To date, toxicity has been primarily managed using drug holidays.

In a study conducted at the Cleveland Clinic, several patients were transitioned to the 2/1 schedule. In this experience, toxicity was significantly decreased with the 2/1 schedule compared to the 4/2 schedule. However, Dreicer notes, at this point, prospective clinical trial data are not available to support these findings but clinical experience suggest better overall quality of life for these patients.
 


Robert Dreicer, MD, MS, chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute and professor of Medicine at the Cleveland Clinic in Ohio, discusses a 2-weeks-on and 1-week-off (2/1) schedule of sunitinib for patients with metastatic renal cell carcinoma (mRCC).

The standard schedule for sunitinib is 4 weeks of treatment followed by 2 weeks of rest (4/2). On this schedule, patients are likely to experience toxicity and dose reductions that result in limited responses to treatment. To date, toxicity has been primarily managed using drug holidays.

In a study conducted at the Cleveland Clinic, several patients were transitioned to the 2/1 schedule. In this experience, toxicity was significantly decreased with the 2/1 schedule compared to the 4/2 schedule. However, Dreicer notes, at this point, prospective clinical trial data are not available to support these findings but clinical experience suggest better overall quality of life for these patients.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x